Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%.
One benefited from positive preliminary data from an early-stage clinical trial. Another surged after an unexpected acquisition by a larger company made the news. And the third stock looks to be rebounding from a big sell-off over the past couple of months.
Which stocks made this week's list of the most humongous performers in all of health care? Find out by watching the following slideshow.
Keith Speights owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.